World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 1 March 2021
Main ID:  NCT01359566
Date of registration: 22/05/2011
Prospective Registration: No
Primary sponsor: XenoPort, Inc.
Public title: Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Scientific title: A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Date of first enrolment: May 2011
Target sample size: 228
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01359566
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 3
Countries of recruitment
United States
Contacts
Name:     Study Director
Address: 
Telephone:
Email:
Affiliation:  Indivior Inc.
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Has multiple sclerosis (MS) based on Poser or McDonald Criteria (all subtypes of MS
will be accepted, including relapsing remitting, primary or secondary progressive, if
disease is stable per exclusion criteria).

2. Maximum Ashworth Score Scale score of = 2 in at least one of the following muscle
groups on either side of the body: hip abductors/adductors, knee flexors/extensors,
ankle flexors/extensors.

3. Expanded Disability Status Scale (EDSS) rating between 3.0-8.0 inclusive.

4. If a subject is on disease modifying MS treatment, the dosage, frequency, and route of
administration must be stable for at least 30 days before screening and is expected to
be stable throughout the study.

5. Spasticity Disability Rating of 2 or higher at Baseline.

6. Willing to discontinue and refrain from using for the duration of the study drugs for
the treatment of spasticity or likely to affect spasticity (including, but not limited
to, baclofen, tizanidine, diazepam, clonazepam, metaxalone, dantrolene,
cyclobenzaprine, carisoprodol, clonidine, vigabatrin, valproic acid and cannabis).

Exclusion Criteria:

1. Spasticity due to neurological disorder other than MS or other conditions that may
confound the assessment of spasticity.

2. Subject has clinically evident muscle contractures resulting in irreversible
spasticity in lower extremities.

3. Subjects who have suffered an acute relapse of MS (as determined by the Investigator)
within 90 days prior to Screening, or have had more than 1 relapse within the year
prior to Screening

4. Botulinum toxin injection within 6 months of Screening or has current residual
associated side effects at Screening.

5. Subjects receiving concomitant medication from more than one of the following three
drug classes: (Antiepileptic drugs, Tricyclic anti-depressants and Opioids)

6. Subjects on the following medications, at doses above the specified limits, are
excluded if they cannot maintain a level within these limits

- Gabapentin = 1800 mg per day or pregabalin = 150 mg per day

- Amitriptyline = 75 mg per day or nortriptyline = 75 mg per day

- Opioids = 30 mg morphine equivalents per day.

7. Evidence of unstable or severe systemic illness, including but not limited to:
Cardiovascular disease (e.g., chronic ventricular arrhythmia, unstable angina or CHF),
respiratory disease (e.g., sleep apnea, COPD requiring oxygen therapy or
hospitalization in last year), endocrine disease, hepatic disease (e.g., chronic
active hepatitis), renal disease, or immunodeficiency.



Age minimum: 18 Years
Age maximum: 70 Years
Gender: All
Health Condition(s) or Problem(s) studied
Multiple Sclerosis
Intervention(s)
Drug: Arbaclofen placarbil 45 mg BID
Drug: Placebo
Drug: Arbaclofen placarbil 15 mg BID
Drug: Arbaclofen placarbil 30 mg BID
Primary Outcome(s)
Change from Baseline in Maximum Ashworth Scale score (6 hour post-dose time point) [Time Frame: 10-weeks]
Patient Global Impression of Change (PGIC) score [Time Frame: 10-weeks]
Secondary Outcome(s)
Change in weekly average VAS score of sleep quality [Time Frame: Week 10]
Change in weekly average severity of pain score associated with muscle spasm. [Time Frame: Week 10]
Change in the overall Modified PRISM score [Time Frame: Weeks 4, 6, 10]
Secondary ID(s)
XP-B-089
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey